Home / Events / P2.02.39 Fulzerasib, a KRAS-G12C Inhibitor, Has Synergistic Antitumor Effect With Omeprazole Pretreatment in KRAS G12C NSCLC First published 10/3/2026, 1:33:15 AM · Last updated 10/3/2026, 1:33:15 AM
P2.02.39 Fulzerasib, a KRAS-G12C Inhibitor, Has Synergistic Antitumor Effect With Omeprazole Pretreatment in KRAS G12C NSCLC A journal article reports that combining the KRAS G12C inhibitor fulzerasib with omeprazole pretreatment produced synergistic antitumor effects in KRAS G12C non-small cell lung cancer. The supplied source data include only the title, publisher, and publication date, with no methods, results detail, or clinical stage.
Illustrative image: " a Free text subject eligibility criteria from an example PM trial protocol. Arm A is enrolling patients with colorectal cancer and any KRAS G12 mutation except G12C. Arm B is enrolling patients with EGFR altered (specifically EGFR exon 19 insertions or EGFR amplifications) solid tumors except breast cancer. b Trial details transformed into CTML, with curated information related to basic trial metadata (orange) and the treatment arms (dark blue) containing specific genomic (turquoise) and clini — Authors of the study: Harry Klein, Tali Mazor, Ethan Siegel, Pavel Trukhanov, Andrea Ovalle, Catherine Del Vecchio Fitz, Zachary Zwiesler, Priti Kumari, Bernd Van Der Veen, Eric Marriott, Jason Hansel, Joyce Yu, Adem Albayrak, Susan Barry, Rachel B. Keller, Laura E. MacConaill, Neal Lindeman, Bruce E. Johnson, Barrett J. Rollins, Khanh T. Do, Brian Beardslee, Geoffrey Shapiro, Suzanne Hector-Barry, John Methot, Lynette Sholl, James Lindsay, Michael J. Hassett & Ethan Cerami/Wikimedia Commons , CC BY 4.0 Categories: science-and-space, public-health, positive-progress
Generated scores Scores are based on the cited reporting and use a 1–10 scale. Read the methodology .
Confidence 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach 2/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity 7/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10). Why it matters This reported drug synergy could influence ongoing research into treatments for KRAS G12C NSCLC.
Sources Report an issue 
